Bruce & Co. Inc. Has $5.17 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Bruce & Co. Inc. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 21.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,895 shares during the period. Supernus Pharmaceuticals accounts for approximately 1.5% of Bruce & Co. Inc.’s portfolio, making the stock its 24th biggest holding. Bruce & Co. Inc. owned 0.17% of Supernus Pharmaceuticals worth $5,169,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Systematic Financial Management LP grew its stake in shares of Supernus Pharmaceuticals by 23.6% in the first quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after acquiring an additional 71,853 shares during the last quarter. Sei Investments Co. increased its position in Supernus Pharmaceuticals by 5.0% during the first quarter. Sei Investments Co. now owns 162,406 shares of the specialty pharmaceutical company’s stock worth $8,395,000 after acquiring an additional 7,795 shares during the period. First Trust Advisors LP raised its stake in Supernus Pharmaceuticals by 56.4% during the 1st quarter. First Trust Advisors LP now owns 46,627 shares of the specialty pharmaceutical company’s stock valued at $2,410,000 after purchasing an additional 16,823 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Supernus Pharmaceuticals by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 321 shares during the last quarter. Finally, Summit Global Investments boosted its holdings in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 256 shares during the period.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $47.19 on Friday. The company has a market capitalization of $2.74 billion, a PE ratio of -92.53, a P/E/G ratio of 1.00 and a beta of 0.54. The company’s fifty day moving average is $46.55 and its 200-day moving average is $49.27. Supernus Pharmaceuticals, Inc. has a 52 week low of $32.51 and a 52 week high of $59.68.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.